Observational studyBMC gastroenterology2026
Endoscopic retrograde appendicitis therapy versus sub-endoscopic retrograde appendicitis therapy for acute appendicitis: a retrospective observational cohort study.
Observational study in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute appendicitis is a common acute abdominal emergency. Laparoscopic appendectomy (LA) carries risks such as bleeding, infection, and negative procedures. Endoscopic retrograde appendicitis therapy (ERAT) is minimally invasive but cannot directly visualize the appendiceal cavity. The novel eyeMax disposable biliary imaging system enables direct observation of the appendix cavity during sub-endoscopic retrograde appendicitis therapy (SERAT), overcoming key limitations of ERAT. The aim of this study is to compare the effectiveness and clinical outcomes of ERAT with SERAT in treating acute appendicitis.
methodThis retrospective study analyzed 60 patients undergoing ERAT and 97 undergoing SERAT for acute appendicitis at Shandong Provincial Third Hospital, China, from November 2021 to September 2024. Propensity score matching (PSM, 1:1) was performed to balance baseline characteristics, yielding 55 pairs of patients. Baseline data, procedural indicators, short-term recovery, and long-term recurrence were compared.
resultsBaseline characteristics were generally comparable between the two groups before and after PSM. After matching, SERAT was associated with significantly shorter operation time and intubation time than ERAT (24.69 vs. 42.65 min, P < 0.001; 96.38 vs. 241.38 s, P < 0.001). The technical success rate was significantly higher in the SERAT group than in the ERAT group (53/55 vs. 47/55, P = 0.047). No significant differences were found in fecalith removal, 6-hour VAS score, hospital stay, or hospitalization cost. Direct visualization in the SERAT group showed inner-wall congestion and edema in 100% of cases, intracavitary fecaliths in 54.4%, and intraluminal pus in 89%. During follow-up, recurrence-free survival was significantly better in the SERAT group ( P = 0.036). Among patients with follow-up data, recurrence occurred in 3/55 (5.4%) patients in the SERAT group and 11/55(20%) patients in the ERAT group. No long-term adverse events were observed in either group.
conclusionSERAT is an effective and safe approach for the diagnosis and treatment of acute appendicitis, offering shorter operation and intubation times, a lower recurrence rate, and minimally invasive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.